AVENUE THERAPEUTICS, INC.
ATXI · OTCMCIK 1644963fmd_0J9VRD98VBMP3WYTA7S5VS8BTGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 43 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | – | 0 | 1 |
| Research and development | 1 | 7 | 18 | 22 | 3 | 1 | 3 | 6 | 7 | 1 |
| Total operating expenses | – | – | – | – | – | – | – | – | 11 | 4 |
| Operating income | (2) | (11) | (22) | (26) | (5) | (4) | (8) | (15) | (11) | (3) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | 0 | 0 | 0 | – | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Net income | (3) | (12) | (22) | (26) | (5) | (4) | (4) | (10) | (12) | (3) |
| Net income to common shareholders | – | – | – | – | – | – | (4) | (10) | (12) | – |